|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bevacizumab plus infusional 5-fluorouracil,leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy:A pilot study显示文摘瞄准:与 infusional 评估 bevacizumab 的联合 5 氟尿嘧啶(5-FU ) ,甲酰四氢叶酸(LV ) 和在有先进颜色的病人的 irinotecan (FOLFIRI ) 有包括 irinotecan 和 oxaliplatin 的联合政体的表面的癌症(CRC ) pretreated。方法:十四个病人(中部的年龄 56 年) 与先进 CRC,都在基于 oxaliplatin 、基于 irinotecan 的联合化疗以后进行了,在这研究被注册。病人们与 irinotecan 的 2 h 注入被对待 d 上的 150 mg/m2 1 ,正 bevacizumab 为 d 上的 90 min 的 5 mg/kg iv 注入 2 ,并且 LV 20 mg/m2 的 iv 注射由 5-FU 的一丸大丸药跟随了 400 mg/m2 然后 22 h 在二连续的天给每 14 d 的 600 mg/m2 的连续注入。结果:化疗的周期的中部的数字是六(范围 3-12 ) 。反应率是 28.5% ,一个病人有完全的回答,并且三个病人有部分回答。八个病人有稳定的疾病。前进的中部的时间是 3.9 瞬间(95% CI 2.0-8.7 ) ,并且中部的全面幸存是 10.9 瞬间(95% CI 9.6-12.1 ) 。等级 3/4 嗜中性白血球减少症在五个病人发生了,并且这些中的二个得了 neutropenic 发烧。等级 3 血尿症和便血发生在一个。等级 2 蛋白尿发生在二个病人。然而,高血压,肠穿孔或 thromboembolic 事件没总共 90 个周期的发生。结论:有 FOLFIRI 的 Bevacizumab 很好被容忍并且在有重重地对待的先进 CRC 的病人的可行治疗。 | Hyuk-Chan Kwon Sung Yong Oh Suee Lee Sung-Hyun Kim Hyo-Jin Kim | 2007 | World Journal of Gastroenterology2007，13，46： | 10 |
| 2 | Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases显示文摘AIM: To identify the clinical features and outcomes of infrequently reported leptomeningeal carcinomatosis (LMC) of gastric cancer.METHODS: We analyzed 54 cases of cytologically confirmed gastric LMC at four institutions from 1994 to 2007.RESULTS: The male-to-female ratio was 32:22, and the patients ranged in age from 28 to 78 years (median,48.5 years). The majority of patients had advanced disease at initial diagnosis of gastric cancer. The clini-cal or pathologic tumor, node and metastasis stage ofthe primary gastric cancer wasin 38 patients (70%).The median interval from diagnosis of the primarymalignancy to the diagnosis of LMC was 6.3 mo, rang-ing between 0 and 73.1 mo. Of the initial endoscopic f indings for the 45 available patients, 23 (51%) of the patients were Bormann typeand 15 (33%) patientswere Bormann type. Pathologically, 94% of cases proved to be poorly differentiated adenocarcinomas. Signet ring cell component was also observed in 40% of patients. Headache (85%) and nausea/vomiting (58%) were the most common presenting symptoms of LMC. A gadolinium-enhanced magnetic resonance imaging was conducted in 51 patients. Leptomeningeal enhancement was noted in 45 cases (82%). Intrathecal (IT) chemotherapy was administered to 36 patients-primarily methotrexate alone (61%), but also in combi-nation with hydrocortisone/± Ara-C (39%). The median number of IT treatments was 7 (range, 1-18). Concomitant radiotherapy was administered to 18 patients, and concomitant chemotherapy to seven patients. Sev-enteen patients (46%) achieved cytological negative conversion. Median overall survival duration from the diagnosis of LMC was 6.7 wk (95% CI: 4.3-9.1 wk). In the univariate analysis of survival duration, hemoglobin, IT chemotherapy, and cytological negative conversion showed superior survival duration (P = 0.038, P = 0.010, and P = 0.002, respectively). However, in our multivariate analysis, only cytological negative conversion was predictive of relatively longer survival duration (3.6, 6.7 and 14.6 wk, P = 0.030, RR: 0.415, 95% CI: 0.188-0.918).CONCLUSION: Although these patients had a fatal clinical course, cytologic negative conversion by IT chemotherapy may improve survival. | Sung Yong Oh Su-Jin Lee Jeeyun Lee Suee Lee Sung-Hyun Kim Hyuk-Chan Kwon Gyeong-Won Lee Jung Hun Kang In Gyu Hwang Joung-Soon Jang Ho Yeong Lim Young Suk Park Won Ki Kang Hyo-Jin Kim | 2009 | World Journal of Gastroenterology2009，15，40： | 10 |
| 3 | Clinicopathologic significance of expression of nuclear factor-kB RelA and its target gene products in gastric cancer patients显示文摘AIM:To assess the prognostic significance of nuclear factor-kB (NF-kB) and its target genes in gastric cancer. METHODS:The tumor tissues of 115 patients with gastric cancer were immunohistochemically evaluated using monoclonal antibodies against NF-kB RelA. Preoperative serum levels of vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) were assessed via enzyme-linked immuno-sorbent assay. C-reactive protein (CRP) and serum amyloid A (SAA) were measured via immunotrubidimetry. RESULTS:Positive rate of NF-kB RelA was 42.6%. NF-kB RelA expression in tumor tissues was also related to serum levels of IL-6 (P = 0.044) and CRP (P = 0.010). IL-6, SAA, CRP were related to depth of invasion, VEGF and SAA were correlated with lymph node metastasis. IL-6, VEGF, SAA and CRP were related to the stage. Univariate analysis demonstrated that immunostaining of NF-kB RelA, levels of IL-6, VEGF, SAA were significantly related with both disease free survival and over-all survival (OS). Multivariate analysis verified that NF-kB RelA [hazard ratio (HR): 3.40, P = 0.024] and SAA (HR: 3.39, P = 0.045) were independently associated with OS. CONCLUSION: Increased expression of NF-kB RelA and high levels of serum SAA were associated with poor OS in gastric cancer patients. | Hyuk-Chan Kwon Sung-Hyun Kim Sung Yong Oh Suee Lee Ji Hyun Lee Jin Seok Jang Min Chan Kim Ki Han Kim Su-Jin Kim Seong-Geun Kim Hyo-Jin Kim | 2012 | World Journal of Gastroenterology2012，18，34： | 9 |
| 4 | Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer显示文摘 | Hyuk-Chan Kwon Sung Hyun Kim Sung Yong Oh Suee Lee Ji Hyun Lee Hong-Jo Choi Ki-Jae Park Mee Sook Roh Seung-Geun Kim Hyo-Jin Kim Jong Hoon Lee | 2012 | Biomarkers2012，，3： | 3 |
| 5 | Phase Ⅱ study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma:consortium for improving survival of lymphoma(CISL)study显示文摘Background:The response rate and survival improvement for rituximab,a CD20-targeting monoclonal antibody,have been demonstrated in marginal zone lymphoma(MZL)as monotherapy and in combination with chemotherapeutic regimens,yet relapses still occur despite treatment completion.Thus,extending the period of remission in MZL patients remains an essential goal.This multicenter,single-arm,open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone).The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further investigation.Methods:Prior to rituximab-maintenance therapy,patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV MZL.Rituximab(375 mg/m^(2)),cyclophosphamide(750 mg/m^(2)),and vincristine(1.4 mg/m^(2);maximum 2 mg)were administered via an intravenous infusion on day 1 of each 3-week cycle,while oral prednisolone(100 mg)was given on days 1-5 of each 3-week cycle.The patients who achieved complete response(CR),partial response(PR),or stable disease(SD)to R-CVP treatment,were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m^(2) every 8 weeks for up to 12 cycles.The primary endpoint was progression-free survival(PFS).Secondary endpoints were overall survival(OS)and treatment safety.Results:47 patients were enrolled,of whom,45(96%)received rituximab-maintenance treatment.Fifteen(33%)patients had nodal MZL.Following R-CVP first-line therapy,20(44%),22(49%),and 3(7%)patients achieved CR,PR,and SD,respectively.After a median follow-up of 38.2 months,their observed 3-year PFS rate was 81%.During the rituximab-maintenance,6 PR and 1 SD patients achieved CR following the administration of R-CVP.Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS(P=0.003)and demonstrated a 3-year OS rate of 90%.Rituximab-maintenance therapy was well tolerated,and the common treatment-emergent adverse events were sensory neuropathy(18%),myalgia(13%),fatigue(9%),and neutropenia(9%).Conclusion: Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile. | Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon Deok-Hwan Yang Won Sik Lee Hyo Jung Kim Ho-Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung-Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong-Won Lee Jae Hoon Lee Ho Sup Lee Ho-Jin Shin Cheolwon Suh | 2019 | Cancer Communications2019，39，1： | 2 |
| 6 | Plasma levels of prothrombin fragment F112,D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients显示文摘 | Hyuk CK Sung YO Suee L | 2008 | Jpn J Clin Oncol2008，38，1： | 1 |
| 7 | Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study显示文摘 | Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Suee Lee Dae Ho Lee Jong-Ho Won In Gyu Hwang Min Kyoung Kim Soon Il Lee Yee Soo Chae Deok-Hwan Yang Hye Jin Kang Chul Won Choi Jinny Park Hyo Jung Kim Jung Hye Kwon Ho Sup Lee Gyeong-Won Lee Hyeon Seok E | 2010 | International Journal of Hematology2010，，3： | 1 |
| 8 | Prognostic sig- nificance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy显示文摘 | Suee Lee Sung Yong Oh Sung Hyun Kim | 2013 | BMC Cancer2013，22，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员